Participants 270 316 6
patients with CKD, including dialysis patients
Participants 436 585 6
The Study of Heart and Renal Protection (SHARP) randomized patients with CKD to 20 mg simvastatin plus 10 mg ezetimibe daily versus matching placebo.
Participants 833 892 4
2353 SHARP participants who had functioning vascular access
